ProQR

Last updated

ProQR
Company type Public
Nasdaq:  PRQR
IndustryBiotechnology Pharmaceuticals
Founded2012
Headquarters
Leiden
Key people
Daniel de Boer (CEO)
Products RNA therapeutics
Number of employees
  • 150
Website http://www.proqr.com/

ProQR Therapeutics NV (NASDAQ: PRQR) is a Dutch biotechnology company based in Leiden, the Netherlands, with a presence in Cambridge, Massachusetts, US. [1] The company was funded in 2012 by chief executive officer (CEO) Daniel A. de Boer. It specializes in the development of RNA therapeutics using its RNA editing platform technology called Axiomer. [2]

Contents

History

ProQR was founded in 2012 by chief executive officer (CEO) Daniel A. de Boer and co-founders Henri Termeer, Dinko Valerio and Gerard Platenburg. [3] [4] [5] [6]

The initial pipeline of the company was to develop small-molecule drugs or gene therapy that would treat cystic fibrosis (CF). [7] Positive proof of concept (PoC) was achieved in 2016 with the clinical trial of the molecule QR-010 targeting the gene coding for cystic fibrosis transmembrane conductance regulator (CFTCR) in patients. [7] Subsequently, the company expanded its pipeline into treating other rare diseases, including diseases of the eye. [7]

In 2017, a spin-out of ProQR named Amylon Therapeutics was established in Leiden with the focus on the development of therapies for the central nervous system. [8]

In 2021, ProQR announced a collaboration with Eli Lilly and Company on the Axiomer technology focused on "genetic disorders in the liver and nervous system". They signed a deal under which ProQR would receive US$50 million ($20 million upfront) and an equity investment of $30 million. [9] The relationship between the two firms "deepened" in 2022 with expansion of the indications engagement and a $75 million cash infusion which included an equity stake. [10]

In 2022, the company announced it would focus exclusively on advancing its RNA editing technology. [11]

Projects

ProQR is an RNA editing company targeting genetic diseases by focusing on making changes to the RNA. [12] The firm's RNA editing technology, called Axiomer can make targeted single nucleotide changes to RNA. [13] ProQR's proprietary Axiomer technology is based on short strands of synthetic RNA called editing oligonucleotides, or EONs. EONs are designed to specifically bind to the target (single stranded) RNA and mimic the double stranded structure that normally attracts an enzyme called Adenosine Deaminase Acting on RNA (ADAR). An EON can attract ADAR to a specific location in an RNA to make an A-to-I edit. This technology can be used to correct an RNA with a disease-causing mutation back to a normal RNA, or change a protein so that it will have a new function that helps prevent or treat disease.

The company's pipeline as of 2023 includes discovery stage programs addressing areas of high unmet medical need: AX-0810 for Cholestatic Diseases targeting NTCP, and AX-1412 for Cardiovascular Disease targeting B4GALT1. [14]

See also

Related Research Articles

Genentech, Inc. is an American biotechnology corporation headquartered in South San Francisco, California. It became an independent subsidiary of Roche in 2009. Genentech Research and Early Development operates as an independent center within Roche. Historically, the company is regarded as the world's first biotechnology company.

In genetics, a nonsense mutation is a point mutation in a sequence of DNA that results in a nonsense codon, or a premature stop codon in the transcribed mRNA, and leads to a truncated, incomplete, and possibly nonfunctional protein product. Nonsense mutations are not always harmful; the functional effect of a nonsense mutation depends on many aspects, such as the location of the stop codon within the coding DNA. For example, the effect of a nonsense mutation depends on the proximity of the nonsense mutation to the original stop codon, and the degree to which functional subdomains of the protein are affected. As nonsense mutations leads to premature termination of polypeptide chains; they are also called chain termination mutations.

<span class="mw-page-title-main">Vertex Pharmaceuticals</span> American pharmaceutical company

Vertex Pharmaceuticals Incorporated is an American biopharmaceutical company based in Boston, Massachusetts. It was one of the first biotech firms to use an explicit strategy of rational drug design rather than combinatorial chemistry. It maintains headquarters in South Boston, Massachusetts, and three research facilities, in San Diego, California, and Milton Park, Oxfordshire, England.

Christoph Westphal is an American biomedical businessman.

Santaris Pharma A/S was a biopharmaceutical company founded in 2003 in Copenhagen, Denmark. The company also had a branch in San Diego, California that opened in 2009. Created by a merger between Cureon and Pantheco, Santaris developed RNA-targeted medicines using a Locked Nucleic Acid (LNA) Drug Platform and Drug Development Engine.

Alexion Pharmaceuticals, a subsidiary of AstraZeneca, is a pharmaceutical company headquartered in Boston, Massachusetts that specializes in orphan drugs to treat rare diseases.

AbbVie Inc. is an American pharmaceutical company headquartered in North Chicago, Illinois. It is ranked sixth on the list of largest biomedical companies by revenue. In 2023, the company’s seat in Forbes Global 2000 was 74. The company's primary product is Humira (adalimumab), administered via injection. It is approved to treat autoimmune diseases including rheumatoid arthritis, Crohn's disease, plaque psoriasis, and ulcerative colitis.

<span class="mw-page-title-main">Moderna</span> American biotechnology company

Moderna, Inc. is a pharmaceutical and biotechnology company based in Cambridge, Massachusetts, that focuses on RNA therapeutics, primarily mRNA vaccines. These vaccines use a copy of a molecule called messenger RNA (mRNA) to carry instructions for proteins to produce an immune response. The company's name is derived from the terms "modified", "RNA", and "modern".

Alnylam Pharmaceuticals, Inc. is an American biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts. In 2016, Forbes included the company on its "100 Most Innovative Growth Companies" list.

<span class="mw-page-title-main">Henri Termeer</span>

Henri A. Termeer was a Dutch biotechnology executive and entrepreneur who is considered a pioneer in corporate strategy in the biotechnology industry for his tenure as CEO at Genzyme. Termeer created a business model adopted by many others in the biotech industry by garnering steep prices— mainly from insurers and government payers— for therapies for rare genetic disorders known as orphan diseases that mainly affect children. Genzyme uses biological processes to manufacture drugs that are not easily copied by generic-drug makers. The drugs are also protected by orphan drug acts in various countries which provides extensive protection from competition and ensures coverage by publicly funded insurers. As CEO of Genzyme from 1981 to 2011, he developed corporate strategies for growth including optimizing institutional embeddedness nurturing vast networks of influential groups and clusters: doctors, private equity, patient-groups, insurance, healthcare umbrella organizations, state and local government, and alumni. Termeer was "connected to 311 board members in 17 different organizations across 20 different industries" He has the legacy of being the "longest-serving CEO in the biotechnology industry.

Arcturus Therapeutics Holdings Inc. is an American RNA medicines biotechnology company focused on the discovery, development and commercialization of therapeutics for rare diseases and infectious diseases. Arcturus has developed proprietary lipid nanoparticle RNA therapeutics for nucleic acid medicines including small interfering RNA (siRNA), messenger RNA (mRNA), gene editing RNA, DNA, antisense oligonucleotides, and microRNA.

<span class="mw-page-title-main">Ionis Pharmaceuticals</span> Biotechnology company

Ionis Pharmaceuticals, Inc. is a biotechnology company based in Carlsbad, California, that specializes in discovering and developing RNA-targeted therapeutics. The company has three commercially approved medicines: Spinraza (Nusinersen), Tegsedi (Inotersen), and Waylivra (Volanesorsen) and has four drugs in pivotal studies: tominersen for Huntington’s disease, tofersen for SOD1-ALS, AKCEA-APO(a)-LRx for cardiovascular disease, and AKCEA-TTR-LRx for all forms of TTR amyloidosis.

Roivant Sciences Ltd. is a healthcare company focused on applying technology to drug development and building subsidiary biotech and healthcare technology companies. It was founded in 2014 by Vivek Ramaswamy.

Arrakis Therapeutics is a biopharmaceutical company developing oral medicines that target RNA to treat a range of diseases. The company is based in Waltham, Massachusetts, and was founded in 2015 by Jennifer Petter, now the company's Chief Innovation Officer. In October 2016, Michael Gilman, a former Biogen executive, was named CEO.

<span class="mw-page-title-main">Insilico Medicine</span> Biotechnology company

Insilico Medicine is a biotechnology company based in Pak Shek Kok, Hong Kong in Hong Kong Science Park near the Chinese University of Hong Kong, and in New York, at The Cure by Deerfield. The company combines genomics, big data analysis, and deep learning for in silico drug discovery.

<span class="mw-page-title-main">Intellia Therapeutics</span> American biotechnology company

Intellia Therapeutics, Inc. is an American clinical-stage biotechnology company focused on developing novel, potentially curative therapeutics leveraging CRISPR-based technologies. The company's in vivo programs use intravenously administered CRISPR as the therapy, in which the company's proprietary delivery technology enables highly precise editing of disease-causing genes directly within specific target tissues. Intellia's ex vivo programs use CRISPR to create the therapy by using engineered human cells to treat cancer and autoimmune diseases.

<span class="mw-page-title-main">Jeffrey Leiden</span> CEO of biotechnology company

Jeffrey Leiden is an American businessman who is the executive chairman of Vertex Pharmaceuticals, a biotechnology company based in Boston, Massachusetts. He was initially appointed to the board of directors of the company in 2009 and was CEO and president from February 2012 to March 2020.

<span class="mw-page-title-main">Ultragenyx</span> American biopharmaceutical company

Ultragenyx is an American biopharmaceutical company involved in the research and development of novel products for treatment of rare and ultra-rare genetic diseases for which there are typically no approved treatments and high unmet medical need. The company works with multiple drug modalities including biologics, small molecule, gene therapies, and ASO and mRNAs in the disease categories of bone, endocrine, metabolic, muscle and CNS diseases.

<span class="mw-page-title-main">CRISPR Therapeutics</span> Swiss-American biotechnology company

CRISPR Therapeutics AG is a Swiss–American biotechnology company headquartered in Zug, Switzerland. It was one of the first companies formed to utilize the CRISPR gene editing platform to develop medicines for the treatment of various rare and common diseases. The company has approximately 500 employees and has offices in Zug, Switzerland, Boston, Massachusetts, San Francisco, California and London, United Kingdom. Its manufacturing facility in Framingham, Massachusetts won the Facilities of the Year Award (FOYA) award in 2022. The company’s lead program, exagamglogene autotemcel, or exa-cel, was granted regulatory approval by the US Food and Drug Administration (FDA) in December 2023.

Precision BioSciences, Inc. is a publicly traded American clinical stage gene editing company headquartered in Durham, North Carolina. Founded in 2006, Precision is focused on developing both in vivo and ex vivo gene editing therapies using its proprietary "ARCUS" genome editing platform.

References

  1. ↑ Let's Chat About...ProQR's work in treatments for inherited retinal disease. Hope in Focus. YouTube. 31 January 2022. Retrieved 11 February 2022.
  2. ↑ "Axiomer RNA editing technology – A novel way to repair RNA". www.proqr.com. Retrieved 14 June 2023.
  3. ↑ Weisman, Robert (20 January 2018). "Henri Termeer isn't exactly settling into retirement". The Boston Globe . Boston Globe Media Partners, LLC. Retrieved 11 February 2022.
  4. ↑ McBride, Ryan (10 May 2013). "Henri Termeer rediscovers the 'Genzyme feel' in world of biotech startups". FierceBiotech. FierceMarkets Inc. Retrieved 11 February 2022.
  5. ↑ Carroll, John (9 September 2014). "Termeer-backed ProQR lays out terms for $75M IPO". FierceBiotech. FierceMarkets Inc. Retrieved 11 February 2022.
  6. ↑ Taylor, Nick Paul (13 September 2017). "ProQR spins out CNS assets to form RNA rare disease biotech". FierceBiotech. FierceMarkets Inc. Retrieved 11 February 2022.
  7. 1 2 3 Rodríguez Fernández, Clara (12 March 2018). "A Dutch Company on the Quest Against Cystic Fibrosis". LaBiotech.eu. Retrieved 11 February 2022.
  8. ↑ Rodriguez Fernandez, Clara (14 February 2017). "New Dutch Spin Out will Treat Stroke with RNA Therapy". LaBiotech.eu. Retrieved 11 February 2022.
  9. ↑ Adams, Ben (8 September 2021). "Eli Lilly follows up MiNA pact with a 2nd $1B-plus RNA collab, this time with ProQR". FierceBiotech. FierceMarkets Inc. Retrieved 11 February 2022.
  10. ↑ Newman, Christoper (22 December 2022). "Lilly pays $75M to widen RNA editing deal with ProQR". BiopharmaDive. Archived from the original on 22 December 2022. Retrieved 23 December 2022.
  11. ↑ "ProQR to Focus Exclusively on Axiomer RNA-editing Technology and Partner Ophthalmology Programs". www.proqr.com. ProQR Therapeutics. Retrieved 14 June 2023.
  12. ↑ Van Zuidam, Joanne (22 September 2017). "The Art of Editing RNA". Drug Discovery Trends. Retrieved 4 April 2018.
  13. ↑ Dale, Alex (13 February 2018). "ProQR Tackles Blindness Caused by a Rare". LaBiotech.eu. Retrieved 11 February 2022.
  14. ↑ "Pipeline". ProQR Therapeutics. Retrieved 6 December 2023.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.